Lv4
434 积分 2025-07-30 加入
The antibody–drug conjugate landscape
15天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
15天前
已完结
The Use of Real‐World Evidence for Regulatory Decisions in China
20天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已关闭
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
3个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3个月前
已完结
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
3个月前
已完结
Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA
3个月前
已完结
皖公网安备34019202002308
